Literature DB >> 33629154

The Clinical Prognosis of Presence and Location of Late Gadolinium Enhancement by Cardiac Magnetic Resonance Imaging in Patients with Hypertrophic Cardiomyopathy: a Single-Center Cohort Study.

Xiaoping Li1,2, Li Lai3, Rong Luo4, Hao Yang5, Huihui Ma5, Zhenglin Yang6, Shihua Zhao7, Wilber Su8, Wei Hua9.   

Abstract

Increasing data have indicated that late gadolinium enhancement (LGE) in cardiac magnetic resonance (CMR) images is associated with the clinical prognosis of hypertrophic cardiomyopathy (HCM). Recently, pioneer studies indicated that the location of LGE in CMR images also had potential predictive value for HCM prognosis. The aim of the present study was to investigate the prognostic value of the location of LGE for HCM. This present cohort study included 557 HCM patients who underwent LGE-CMR imaging, and the LGE location was classified as LGE in interventricular septum only (IVS-LGE) and LGE outside the IVS with or without IVS involvement (other than IVS-LGE). All-cause mortality, cardiovascular mortality/cardiac transplantation, and sudden cardiac death (SCD) were evaluated. During a mean follow-up time of 83.0±37.8 months, there was a significantly higher all-cause mortality, cardiovascular mortality/cardiac transplantation, and SCD in patients with other than IVS-LGE than in those with IVS-LGE. Multivariate Cox regression suggested that other than IVS-LGE were one of independent prognostic predictors. Risk reclassification for prognosis showed that there were no differences between the prediction values of the presence of LGE and the location of LGE. The presence and location of LGE in CMR images are equally independent prognostic predictors of HCM, and other than IVS-LGE location is associated with an adverse clinical prognosis. Prognosis Trial Registration: ChiCTR-ONRC-11001902.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Keywords:  Hypertrophic cardiomyopathy; LGE-CMR; Location; Prognosis

Mesh:

Substances:

Year:  2021        PMID: 33629154     DOI: 10.1007/s12265-021-10107-x

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  2 in total

Review 1.  Prognostic Value of LGE-CMR in HCM: A Meta-Analysis.

Authors:  Zhen Weng; Jialu Yao; Raymond H Chan; Jun He; Xiangjun Yang; Yafeng Zhou; Yang He
Journal:  JACC Cardiovasc Imaging       Date:  2016-07-20

2.  Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.

Authors:  Barry J Maron; Paolo Spirito; Win-Kuang Shen; Tammy S Haas; Francesco Formisano; Mark S Link; Andrew E Epstein; Adrian K Almquist; James P Daubert; Thorsten Lawrenz; Giuseppe Boriani; N A Mark Estes; Stefano Favale; Marco Piccininno; Stephen L Winters; Massimo Santini; Sandro Betocchi; Fernando Arribas; Mark V Sherrid; Gianfranco Buja; Christopher Semsarian; Paolo Bruzzi
Journal:  JAMA       Date:  2007-07-25       Impact factor: 56.272

  2 in total
  2 in total

Review 1.  Risk factors of sudden cardiac death in hypertrophic cardiomyopathy.

Authors:  Ying Hong; Wilber W Su; Xiaoping Li
Journal:  Curr Opin Cardiol       Date:  2022-01-01       Impact factor: 2.108

2.  Association of electrocardiographic markers with myocardial fibrosis as assessed by cardiac magnetic resonance in different clinical settings.

Authors:  George Bazoukis; Sebastian Garcia-Zamora; Göksel Çinier; Sharen Lee; Enes Elvin Gul; Jesús Álvarez-García; Gabi Miana; Mert İlker Hayıroğlu; Gary Tse; Tong Liu; Adrian Baranchuk
Journal:  World J Cardiol       Date:  2022-09-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.